-

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ESS Tech, Inc. (GWH)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 13, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ESS Tech, Inc. (“ESS” or the “Company”) (NYSE: GWH) securities between August 11, 2022 and December 7, 2022, inclusive (the “Class Period”).

If you suffered a loss on your ESS investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/ESS-Tech-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On December 7, 2022, Grizzly Research published a report which alleged, among other things, that ESS’s largest partner, Energy Storage Industries Asia Pacific (“ESI”), is a related party with no real staff, office, or any relevant ongoing business activity. Furthermore, the report claimed that the Company concealed the fact that ESI was a de-facto subsidiary, not a true third party.

On this news, ESS’s stock price fell $0.22, or 7.7%, to close at $2.64 per share on December 7, 2022, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the purported agreement with ESI was in fact an undisclosed related party transaction because ESI was a de-facto subsidiary of ESS masquerading as third-party client; (2) ESS misled investors with their partnership announcement to signal business success to investors; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased or otherwise acquired ESS securities during the Class Period, you may move the Court no later than March 13, 2023 to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

Glancy Prongay & Murray LLP

NYSE:GWH

Release Versions

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com

More News From Glancy Prongay & Murray LLP

Lost Money on Madrigal Pharmaceuticals, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 8.1% Share Price Drop

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 3, 2026 disclosure regarding Madrigal Pharmaceuticals,...

Lost Money on Dave, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 21.25% Share Price Drop

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Dave, Inc. ("Dave" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Dave, Inc. (NASDAQ: DAVE) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 4, 2026 disclosure regarding Dave, Inc. Investors who lost money on Dave, Inc. securities can submi...

Lost Money on MNTN, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 53.62% Share Price Drop

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on MNTN, Inc. ("MNTN" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of MNTN, Inc. (NYSE: MNTN) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 4, 2026 disclosure regarding MNTN, Inc.Investors who lost money on MNTN, Inc. securities can submit th...
Back to Newsroom